InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $15.360 -0.09 (-0.58%)+
Announcement
Release
15 Apr 2026 8:14AM
Price at Release
$15.450
Full Release
download
Summary
Telix Pharmaceuticals Limited announced the successful pricing and upsizing of its US$600 million convertible bonds due 2031, issued by its subsidiary Telix Pharmaceuticals (Investments) Inc. and guaranteed by Telix and Telix Pharmaceuticals (US) Inc. The bonds, initially planned at US$550 million, were increased due to high demand. The conversion price is set at US$13.85 per ordinary share, with a 37.5% conversion premium over the reference share price. Interest on the bonds will be paid quarterly at 1.50% per annum, and they are set to mature on 22 April 2031. Concurrently, Telix will repurchase approximately A$637 million of its existing bonds due 2029, effectively refinancing and canceling over 85% of these bonds. The offering and repurchase are expected to settle on 22 April 2026, supporting Telix's capital management strategy and financial flexibility.
Key Points
  • Telix prices and upsizes US$600 million convertible bonds.
  • Bonds due 2031, issued by Telix Pharmaceuticals (Investments) Inc.
  • 1.50% annual interest rate, payable quarterly.
  • Initial conversion price US$13.85 per ordinary share with 37.5% premium.
  • Concurrent repurchase of A$637 million existing bonds due 2029.
  • Over 85% of existing bonds to be repurchased and canceled.
  • Settlement expected on 22 April 2026.
  • J.P. Morgan acted as Sole Bookrunner and Dealer Manager.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.